In rheumatoid arthritis soluble CD30 ligand is present at high levels and induces apoptosis of CD30+T cells

Immunology Letters

Volumn 161, Issue 2, 2014, Pages 236-240

  Tinazzi, Elisa ^a   Barbieri, Alessandro ^a   Rigo, Antonella ^a   Patuzzo, Giuseppe ^a   Beri, Ruggero ^a   Gerli, Roberto ^b   Argentino, Giuseppe ^a   Puccetti, Antonio ^c   Lunardi, Claudio ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Apoptosis; CD30; CD30 ligand; Rheumatoid arthritis

Indexed keywords

CD30 ANTIGEN; CD30 LIGAND; PROTEIN BINDING;

ADULT; ANTIGEN BINDING CELL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; APOPTOSIS; ARTICLE; CD30+ T CELL; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; T LYMPHOCYTE; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD30; APOPTOSIS; ARTHRITIS, RHEUMATOID; CD30 LIGAND; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN BINDING; T-LYMPHOCYTE SUBSETS;

EID: 84906794516     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.01.007     Document Type: Article

References (34)

1. Horie R., Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998, 10:457-470.
2. Ashkenazi A., Dixit V.M. Death receptors: signalling and modulation. Science 1998, 281:1305-1308.
3. Falini B., Pileri S., Pizzolo G., Dürkop H., Flenghi L., Stirpe F., et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and therapy. Blood 1995, 85:1-14.
4. Carvalho R.F., Ulfgren A.K., Engström M., Klint E., Nilsson G. CD153 in rheumatoid arthritis: detection of a soluble form in serum and synovial fluid and expression by mast cells in the rheumatic synovium. J Rheumatol 2009, 36:501-507.
5. Cerruti A., Schaffer A., Goodwin R.G., Shah S., Zan H., Ely S., et al. Engagement of CD153 (CD30 ligand) by CD30+ T cells inhibits class switch DNA recombination and antibody production in human IgD+IgM+ B cells. J Immunol 2000, 165:786-794.
6. Cerruti A., Kim E.C., Shah S., Schattner E.J., Zan H., Schaffer A., et al. Dysregulation of CD30+ T cells by leukaemia impairs isotype switching in normal B cells. Nat Immunol 2001, 2:150-156.
7. Sun X., Yamada H., Shibata K., Muta H., Tani K., Podack E.R., et al. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. J Immunol 2010, 185:2222-2230.
8. Wiley S.R., Goodwin R.G., Smith C.A. Reverse signalling via CD30 ligand. J Immunol 1996, 157:3635-3639.
9. Chiarle R., Podda A., Prolla G., Podack E.R., Thorbecke G.J., Inghirami G. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via Bcl-2-sensitive pathway. J Immunol 1999, 163:194-205.
10. Gilfillan M.C., Noel P.J., Podack E.R., Reiner S.L., Thompson C.B. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunol 1998, 160:2180-2187.
11. Bengtsson A. The role of CD30 in atopic disease. Allergy 2001, 56:593-603.
12. Polte T., Behrendt A.K., Hansen G. Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol 2006, 118:942-948.
13. Gerli R., Lunardi C., Vinante F., Bistoni O., Pizzolo G., Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. Trends Immunol 2001, 22:72-77.
14. Saraiva M., Smith P., Fallon P.G., Alcami A. Inhibition of type I cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus. J Exp Med 2002, 196:829-839.
15. Tang C., Yamada H., Shibada K., Muta H., Wajjwalku W., Podack E.R., et al. A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J Immunol 2008, 181:6316-6327.
16. Guo Y., Sun X., Shibata K., Yamada H., Muta H., Podack E.R., et al. CD30 is required for activation of a unique subset of interleukin-17A-producing gd T cells in innate immunity against Mycobacterium bovis bacillus Calmette-Guerin infection. IAI 2013, 10:3923-3934.
17. Lin C.Y., Graca L., Cobbold S.P., Waldmann H. Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol 2002, 3:1208-1213.
18. Dai Z., Li Q., Wang Y., Gao G., Diggs L.S., Tellides G., et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 2004, 113:310-317.
19. Gaspal F.M., Kim M.Y., McConnell F.M., Raykundalia C., Bekiaris V., Lane P.J. Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T-cell memory. J Immunol 2005, 174:3891-3896.
20. Zeiser R., Nguyen V.H., Hou J., Beilhack A., Zambricki E., Buess M., et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 2007, 109:2225-2233.
21. Oflazoglu E., Grewal I.S., Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009, 647:174-185.
22. Gerli R., Muscat C., Bistoni O., Falini B., Tomassini C., Agea E., et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (AR) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 1995, 102:547-550.
23. Gerli R., Pitzalis C., Bistoni O., Falini B., Costantini V., Russano A., et al. CD30-positive T cells in rheumatoid arthritis synovitis: mechanisms of recruitment and functional role. J Immunol 2000, 164:4399-4407.
24. Miossec P. Are T cells in rheumatoid synovium aggressors or bystanders?. Curr Opin Rheumatol 2000, 12:185-187.
25. Aarvak T., Chabaud M., Källberg E., Miossec P., Natvig J.B. Changes in Th1/Th2 phenotype of memory T-cell clones from rheumatoid synovium. Scand J Immunol 1999, 50:1-9.
26. Nakamura T., Lee R.K., Nam S.Y., Al-Ramadi B.K., Koni P.A., Bottomly K., et al. Reciprocal regulation of CD30 expression in CD4+ T cells by IL-4 and IFN-γ. J Immunol 1997, 158:2090-2098.
27. Pellegrini P., Berghella A.M., Contasta I., Adorno D. CD30 antigen: not a physiological marker for Th2 cells but an important costimulator molecule in the regulation of the balance between Th1/Th2 response. Transplant Immunol 2003, 12:49-61.
28. Gerli R., Bistoni O., Lunardi C., Giacomelli R., Tomassini C., Bigini P., et al. Soluble CD30 in rheumatoid arthritis as predictor of good response to second line therapy. Rheumatology 1999, 38:1282-1284.
29. Gerli R., Lunardi C., Bartoloni Bocci E., Bobbio-Pallavicini F., Schillaci G., Caporali R., et al. Anti-TNFa response in rheumatoid arthritis patients is associated with an increase in serum soluble CD30 levels. J Rheumatol 2008, 35:14-19.
30. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., et al. 2010 Rheumatoid Arthritis Classification criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum 2010, 62:2569-2581.
31. Neogi T., Aletaha D., Silman A.J., Naden R.L., Felson D.T., Aggarwal R., et al. The 2010 American college of Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis. Phase 2 methodological report. Arthritis Rheum 2010, 62:2582-2591.
32. Lunardi C., Bason C., Navone R., Millo E., Damonte G., Corrocher R., et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human CMV late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000, 6:1183-1186.
33. Vinante F., Rigo A., Papini E., Cassatella M.A., Pizzolo G. Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. Blood 1999, 93:1715-1723.
34. Vinante F., Rigo A., Scupoli M.T., Pizzolo G. CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. Blood 2002, 99:52-60.